ScreenPoint Medical is the leading developer of AI driven image analysis technology which enables the automated reading of mammograms and digital breast tomosynthesis examinations. With proven accuracy matching that of experienced radiologists, ScreenPoint's Transpara® system is the most advanced commercially available (FDA cleared and CE marked for both 2D and 3D mammography), exploiting Big Data, Deep Learning and the latest advances in Artificial Intelligence to provide an evidence based multi-vendor solution. ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, two internationally respected experts in breast imaging, machine learning and computer aided detection. The company’s Head Office is in Nijmegen, The Netherlands. Transpara is currently being used in over 15 countries including USA, France, Germany and the Netherlands. We focus on helping to improve breast cancer survival rates by detecting cancer earlier so that treatment can be more effective and less invasive.